Phaseline

Companies › Granata Bio

Granata Bio: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Genitourinary; next expected readout Nov 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
hMG (human menopausal gonadotropin)
Follicle-stimulating hormone (FSH) and luteinizing hormone (LH) receptor agonist
FSHR, LHRPhase 3Infertility (IVF Patients)Nov 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07216742hMG (human menopausal gonadotropin)Phase 3Infertility (IVF Patients)GenitourinaryNov 2028

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

FSHR (1) LHR (1)

Companies with the same targets

Clinique Ovo Qilu Pharmaceutical LG Chem Merck KGaA

Companies built like this

Fertility Center of Las Vegas Zydus Lifesciences Dimerix Bioscience Chengdu Qingshan Likang Pharmaceutical Hope Medicine (Nanjing)

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.